Get Adobe Flash player

lipidConclusion

The HMG-CoA reductase inhibitor (statin) rosuvastatin is widely available for use in the management of dyslipidemia.
Recently approved in the US to slow the progression of atherosclerosis as part of a strategy to lower LDL-C and TC to target levels.


Rosuvastatin has greater lipid-lowering efficacy than other statins, and significantly more patients receiving rosuvastatin than other statins achieve LDL-C goals.
Rosuvastatin delayed the progression of carotid atherosclerosis in patients with subclinical carotid atherosclerosis, moderately elevated cholesterol levels, and a low risk of cardiovascular disease in a primary prevention trial.
The results of METEOR suggest a possible role for the earlier use of rosuvastatin in primary prevention,
Significant regression of atherosclerosis was seen with rosuvastatin 40 mg/day in patients with established coronary heart disease (CHD)
In the ASTEROID trial, supporting the use of intensive lipid lowering in secondary prevention patients
Rosuvastatin is generally well tolerated.
Thus, rosuvastatin is an important lipid-lowering treatment option that has been shown to cause regression of atherosclerosis in secondary prevention patients, and has a potential future role in delaying atherosclerosis in primary prevention patients.

Xem/ Đọc toàn vănTrích Hội nghị Nội tiết -Đái tháo đường và Rối loạn chuyển hóa miền Trung Tây Nguyên mở rộng lần thứ VIII- Tp Vinh- Nghệ An.

 

Add comment


Security code
Refresh

Hội Nội Tiết- Đái Tháo Đường Miền Trung Việt Nam

Diabetes- Endocrinology- Metabolism Association of central Vietnam

Tổng biên tập: NGƯT.GS.TS. NGUYỄN HẢI THỦY

Liên hệ ban biên tập: 0903574457, email: nhthuy52@gmail.com hoặc admin@dema-cvn.com

Năm xuất bản: 12/2010